TSX:RVX - CA76128M1086 - Common Stock
The current stock price of RVX.CA is 0.1025 CAD. In the past month the price increased by 2.5%. In the past year, price increased by 13.89%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
EDT.CA | SPECTRAL MEDICAL INC | N/A | 425.87M | ||
FRX.CA | FENNEC PHARMACEUTICALS INC | N/A | 343.98M | ||
EPRX.CA | EUPRAXIA PHARMACEUTICALS INC | N/A | 266.82M | ||
TH.CA | THERATECHNOLOGIES INC | N/A | 204.61M | ||
HBP.CA | HELIX BIOPHARMA CORP | N/A | 103.88M | ||
WLLW.CA | WILLOW BIOSCIENCES INC | N/A | 97.56M | ||
MDNA.CA | MEDICENNA THERAPEUTICS CORP | N/A | 90.92M | ||
BLU.CA | BLUENERGIES LTD | N/A | 82.42M | ||
NRX.CA | NUREXONE BIOLOGIC INC | N/A | 66.41M | ||
COV.CA | COVALON TECHNOLOGIES LTD | 18.46 | 65.81M | ||
MSCL.CA | SATELLOS BIOSCIENCE INC | N/A | 60.21M | ||
SVA.CA | SERNOVA BIOTHERAPEUTICS INC | N/A | 45.90M |
Resverlogix Corp. engages in the research and development of pharmaceutical products for cardiovascular diseases. The company is headquartered in Calgary, Alberta and currently employs 18 full-time employees. The company went IPO on 2001-10-12. The firm focuses on the development of a new class of therapeutics: bromodomain and extraterminal domain (BET) protein inhibitors. BET proteins play a central role in epigenetics and enable the transcription of disease-causing genes. Its small molecule BET inhibitors are designed to exploit this central epigenetic role to regulate gene expression and tackle the root causes of chronic diseases. The firm's clinical program focuses on evaluating the lead epigenetic candidate apabetalone for the treatment of cardiovascular disease, associated comorbidities, and post-COVID-19 conditions. The company partners with EVERSANA to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.
RESVERLOGIX CORP
300-4820 Richard Rd SW
Calgary ALBERTA T3E 6L1 CA
CEO: Donald J. McCaffrey
Employees: 18
Phone: 14032549252
The current stock price of RVX.CA is 0.1025 CAD. The price decreased by -2.38% in the last trading session.
The exchange symbol of RESVERLOGIX CORP is RVX and it is listed on the Toronto Stock Exchange exchange.
RVX.CA stock is listed on the Toronto Stock Exchange exchange.
RESVERLOGIX CORP (RVX.CA) has a market capitalization of 29.36M CAD. This makes RVX.CA a Nano Cap stock.
RESVERLOGIX CORP (RVX.CA) currently has 18 employees.
RESVERLOGIX CORP (RVX.CA) has a support level at 0.1 and a resistance level at 0.11. Check the full technical report for a detailed analysis of RVX.CA support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
RVX.CA does not pay a dividend.
RESVERLOGIX CORP (RVX.CA) will report earnings on 2025-11-10.
RESVERLOGIX CORP (RVX.CA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.05).
ChartMill assigns a technical rating of 8 / 10 to RVX.CA. When comparing the yearly performance of all stocks, RVX.CA is one of the better performing stocks in the market, outperforming 90.2% of all stocks.
Over the last trailing twelve months RVX.CA reported a non-GAAP Earnings per Share(EPS) of -0.05. The EPS increased by 12.03% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -143.27% | ||
ROE | N/A | ||
Debt/Equity | N/A |